XML 57 R45.htm IDEA: XBRL DOCUMENT

Transition Period Comparative Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2021


(in millions)	Year Ended		Six-month Period Ended
Consolidated Statement of Operations Data:	December 31, 2020		December 31, 2019
Molecular diagnostic testing	$	513.5	$	353.1
Pharmaceutical and clinical services	43.6		28.3
Total revenue	557.1		381.4
Costs and expenses:
Cost of molecular diagnostic testing	157.9		82.2
Cost of pharmaceutical and clinical services	20.3		17.1
Research and development expense	73.3		40.1
Selling, general and administrative expense	496.9		270.4
Goodwill and long-lived asset impairment charges	98.4		1.3
Total costs and expenses	846.8		411.1
Operating loss	(289.7)		(29.7)
Other income (expense):
Interest income	2.0		1.7
Interest expense	(11.2)		(5.4)
Other	15.3		(0.3)
Total other income (expense)	6.1		(4.0)
Loss before income taxes	(283.6)		(33.7)
Income tax benefit	(59.9)		(4.8)
Net loss	(223.7)		(28.9)
Net loss attributable to non-controlling interest	(0.1)		—
Net loss attributable to Myriad Genetics Inc. stockholders	$	(223.6)	$	(28.9)
Loss per share:
Basic	$	(2.99)	$	(0.39)
Diluted	$	(2.99)	$	(0.39)
Weighted average shares outstanding:
Basic	74.8		74.1
Diluted	74.8		74.1